Section Arrow
MBX.NASDAQ
- MBX Biosciences Inc.
Quotes are at least 15-min delayed:2026/07/22 16:58 EDT
After Hours
Last
 57.17
-1.13 (-1.94%)
Bid
56.65
Ask
64.35
High 58.3 
Low 57.17 
Volume 5.94K 
Regular Hours (Closed)
Last
 58.3
-1.98 (-3.28%)
Day High 
60.645 
Prev. Close
60.28 
1-M High
66.55 
Volume 
663.40K 
Bid
56.65
Ask
64.35
Day Low
57.23 
Open
60.18 
1-M Low
41.9906 
Market Cap 
2.87B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 60.75 
20-SMA 57.37 
50-SMA 43.54 
52-W High 66.55 
52-W Low 9.63 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.17/-4.01
Enterprise Value
2.87B
Balance Sheet
Book Value Per Share
9.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LABTLakewood-Amedex Biotherapeutics Inc3.41+1.55+83.33%-- 
After Hours 3.58 +0.17 +4.99%
KAPAKairos Pharma Ltd.0.3127-0.0453-12.65%-- 
After Hours 0.2775 -0.0352 -11.26%
JUNSJupiter Neurosciences Inc0.1746+0.0049+2.89%-- 
After Hours 0.1706 -0.004 -2.29%
GOSSGossamer Bio0.1446-0.0102-6.59%-- 
After Hours 0.1445 -0.0001 -0.07%
RXRXRecursion Pharmaceuticals2.98-0.1-3.25%-- 
After Hours 2.995 +0.015 +0.50%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.